Blood test strategy may spare kidney patients from unnecessary biopsies
NCT ID NCT04774575
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether using non-invasive blood biomarkers to guide when to perform a biopsy is as safe as doing routine biopsies at set times in kidney transplant recipients. 342 patients were randomly assigned to either a biomarker-guided group or a routine biopsy group. The goal was to see if the biomarker approach could reduce the number of biopsies without missing signs of organ rejection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
biomarker-guided strategy (non-invasive blood tests)
What this could lead to
If successful, this approach could reduce the need for painful and risky routine biopsies in kidney transplant patients, making follow-up safer and more comfortable.
What could go wrong
This is a completed trial, but the strategy may not detect all cases of rejection, and results may not apply to all transplant centers or patient groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bellvitge University Hospital
Barcelona, 08907, Spain
-
Charité-Universitätsmedizin,
Berlin, 10117, Germany
-
Charité-Universitätsmedizin, Berlin
Berlin, 10117, Germany
-
Geneva University Hospitals
Geneva, Canton of Geneva, 1205, Switzerland
-
Nantes Hospital
Nantes, 44000, France
-
Necker Hospital, Paris
Paris, Île-de-France Region, 75015, France
-
Saint-Louis Hospital, Paris
Paris, Île-de-France Region, 75010, France
-
Vall d'Hebron Hospital
Barcelona, 08035, Spain